Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41229   clinical trials with a EudraCT protocol, of which   6756   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-002318-11
    Sponsor's Protocol Code Number:109MS306
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2015-05-08
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2013-002318-11
    A.3Full title of the trial
    Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis
    Estudio abierto, aleatorizado, multicéntrico, de múltiples dosis, comparativo con fármaco activo y con grupos paralelos, sobre la eficacia y la seguridad de BG00012 en niños de 10 a menos de 18 años de edad con esclerosis múltiple recurrente-remitente
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With relapsing-remitting multiple sclerosis (RRMS).
    Un estudio sobre la seguridad y eficacia de BG00012 en sujetos pediatricos con esclerosis múltiple recurrente-remitente
    A.3.2Name or abbreviated title of the trial where available
    CONNECT
    A.4.1Sponsor's protocol code number109MS306
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/027/2013
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBiogen Idec Research Limited
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBiogen Idec Research Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBiogen Idec Research Limited
    B.5.2Functional name of contact pointMedical Director
    B.5.3 Address:
    B.5.3.1Street AddressInnovation House, 70 Norden Road
    B.5.3.2Town/ cityMaidenhead
    B.5.3.3Post codeSL6 4AY
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number3491806 2000
    B.5.6E-mailclinicaltrials@biogenidec.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBG00012
    D.3.2Product code BG00012
    D.3.4Pharmaceutical form Gastro-resistant capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDIMETHYL FUMARATE
    D.3.9.1CAS number 624-49-7
    D.3.9.2Current sponsor codeBG00012
    D.3.9.3Other descriptive nameDIMETHYL FUMARATE
    D.3.9.4EV Substance CodeSUB13608MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number120
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name AVONEX
    D.2.1.1.2Name of the Marketing Authorisation holderBiogen Idec Ltd
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAvonex
    D.3.4Pharmaceutical form Injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNInterferon beta-1a
    D.3.9.1CAS number 220581-49-7
    D.3.9.3Other descriptive nameINTERFERON BETA-1A
    D.3.9.4EV Substance CodeSUB12440MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number7.5 to 30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsing-Remitting Multiple Sclerosis
    Esclerosis múltiple recurrente-remitente
    E.1.1.1Medical condition in easily understood language
    Multiple Sclerosis
    Esclerosis múltiple
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level SOC
    E.1.2Classification code 10029205
    E.1.2Term Nervous system disorders
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level PT
    E.1.2Classification code 10063399
    E.1.2Term Relapsing-remitting multiple sclerosis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The main objectives of the study are as follows:
    ? To evaluate the safety, tolerability, and effect on the disease course of BG00012 (dimethyl fumarate) in pediatric participants with RRMS, as compared with a disease modifying treatment.
    ? To assess pharmacokinetic (PK) and pharmacodynamic (PD) parameters in a representative subset of pediatric participants
    ? To assess health outcomes and evolution of disability
    Los principales objetivos del estudio son los siguientes:
    ? Evaluar la seguridad, tolerabilidad y el efecto de BG00012 en el desarrollo de la enfermedad en niños con EMRR en comparación con un tratamiento modificador de la enfermedad.
    ? Evaluar los parámetros farmacocinéticos (FC) y farmacodinámicos (FD) en un subgrupo representativo de niños afectados.
    ? Evaluar los efectos sobre la salud y la evolución de la discapacidad.
    E.2.2Secondary objectives of the trial
    Not Applicable
    No aplica
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    key inclusion criteria:
    - Must have a body weight of ?30 kg.
    - Must have a diagnosis of RRMS (consensus definition for pediatric RRMS [Krupp 2007]).
    - Must be ambulatory with a baseline EDSS score between 0 and 5.5, inclusive.
    - Must have experienced at least 1 relapse within the last 12 months prior to Day 1, or at least 2 relapses within the last 24 months prior to Day 1, with a prior brain MRI demonstrating lesions consistent with MS, or show evidence of Gd enhancing lesions of the brain on an MRI performed within the 6 weeks prior to Day 1.
    - Must be neurologically stable, with no evidence of relapse within 50 days prior to Day 1 and no evidence of corticosteroid treatment within 30 days prior to Day 1.
    - Subjects of childbearing potential who are sexually active must be willing to practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their final dose of study treatment.
    Criterios de inclusión clave:
    - Debe tener un peso corporal de ?30 kg.
    - Debe tener un diagnóstico de la EMRR (definición de consenso para la EMRR pediátricos [Krupp 2007]).
    - Debe ser ambulatoria con una puntuación EDSS basal entre 0 y 5.5, ambos inclusive.
    - Deben haber experimentado al menos 1 recaída en los 12 meses anteriores al Día 1 o al menos 2 recaídas en los 24 meses previos al día 1, con una RM cerebral anterior que muestre lesiones coherentes con la EM, o evidencia de lesiones potenciadas con Gd del cerebro en una RM realizada durante las 6 semanas anteriores al Día 1.
    - Deben estar estables neurológicamente, sin evidencias de recaída en un periodo de 50 días antes del Día 1 y sin evidencias de haber seguido tratamiento con corticosteroides en los 30 días anteriores al Día 1.
    - Las pacientes en edad fértil y que sean sexualmente activas deben utilizar métodos anticonceptivos eficaces durante el estudio, así como estar dispuestas a, y ser capaces de, continuar con ellas durante al menos 30 días después de su última dosis del tratamiento del estudio
    E.4Principal exclusion criteria
    Key exclusion criteria:
    - Primary progressive, secondary progressive, or progressive relapsing MS (as defined by [Lublin and Reingold 1996]). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Subjects with these conditions may also have superimposed relapses but are distinguished from relapsing remitting subjects by the lack of clinically stable periods or clinical improvement.
    - Disorders mimicking MS, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis), systemic autoimmune disorders (e.g., Sjögren disease, lupus erythematosus), metabolic disorders (e.g., dystrophies), and infectious disorders.
    - History of premalignant or malignant disease. Subjects with basal cell carcinoma that has been completely excised prior to screening will remain eligible.
    - History of severe allergic or anaphylactic reactions, or known drug hypersensitivity to DMF or fumaric acid esters.
    - History of abnormal laboratory results indicative of any significant endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, renal, and/or any other major disease that would preclude participation in a clinical study.
    - History of clinically significant cardiovascular, pulmonary, GI, dermatologic, growth, developmental, psychiatric (including depression), neurologic (other than MS), and/or other major disease that would preclude participation in a clinical study.
    - History of human immunodeficiency virus.
    - An MS relapse that has occurred within 50 days prior to Day 1 AND/OR the subject has not stabilized from a previous relapse prior to Day 1.
    - Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, make the subject unsuitable for enrollment.
    - For the PD/PK subset of subjects: subjects unable to swallow the BG00012 capsule whole.
    Key Treatment history
    - Any previous treatment with Fumaderm (fumaric acid esters) or BG00012.
    - Prior treatment with any of the following: total lymphoid irradiation, cladribine, T-cell or T-cell receptor vaccination, any therapeutic monoclonal antibody, with the exception of rituximab or natalizumab
    - Prior treatment with any of the following medications within the 12 months prior to Day 1: mitoxantrone, cyclophosphamide, rituximab
    - Prior treatment with any of the following medications or procedures within 6 months prior to Day 1: fingolimod, teriflunomide, natalizumab, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, laquinimod, IV immunoglobulin, plasmapheresis or cytapheresis
    - Prior treatment with any of the following within 3 months prior to Day 1: glatiramer acetate, interferon-alpha, interferon ? (subjects who are positive for neutralizing antibodies to interferon-? may receive interferon-? treatment up to 2 weeks prior to Day 1)
    - Treatment with any of the following medications within 30 days prior to Day 1:
    - steroids (IV or oral corticosteroid treatment, including agents that may act through the corticosteroid pathway [e.g., low dose naltrexone]), 4-aminopyridine or related products (except subjects on a stable dose of controlled-release fampridine for 3 months)
    NOTE: Other protocol-defined inclusion/exclusion criteria may apply
    Criterios de exclusión clave:
    -EM recurrente primaria progresiva, secundaria progresiva o progresiva (bajo la definición de [Lublin y Reingold 1996]). Estas enfermedades requieren la presencia de un empeoramiento clínico continuo de la enfermedad durante un periodo mínimo de 3 meses. Los pacientes con estas enfermedades también pueden acumular recaídas pero se diferencian de los pacientes con EM recurrente-remitente por la ausencia de periodos clínicamente estables o de mejora clínica.
    -Trastornos que imitan a la EM, como otras afecciones desmielinizantes (por ejemplo, encefalomielitis aguda diseminada), trastornos autoinmunitarios sistémicos (por ejemplo, síndrome de Sjögren, lupus eritematoso), trastornos metabólicos (por ejemplo, distrofias) y trastornos infecciosos.
    - Antecedentes de enfermedades precancerosas o tumores malignos. Los pacientes con carcinoma basocelular que se ha extirpado completamente antes de la selección siguen siendo aptos.
    - Antecedentes de reacciones alérgicas o anafilácticas graves o hipersensibilidad conocida a DMF o ésteres de ácido fumárico.
    -Antecedentes de resultados analíticos anómalos indicativos de cualquier endocrinopatía, hemopatía, hepatopatía, inmunopatía, metabolopatía, uropatía, nefropatía significativa y/u otros trastornos importantes que puedan ser motivo de exclusión para la participación en un estudio clínico.
    -Antecedentes de enfermedad cardiovascular, pulmonar, gastrointestinal, dermatológica, del crecimiento, del desarrollo, psiquiátrica (incluyendo depresión), neurológica (diferente a la EM) clínicamente significativas y/u otros trastornos importantes que puedan ser motivo de exclusión para la participación en un estudio clínico.
    -Antecedentes de infección por el virus de la inmunodeficiencia humana.
    -Una recaída de la EM que haya tenido lugar en los 50 días anteriores al día 1; O BIEN, el paciente no se ha estabilizado desde una recaída anterior previa al Día 1.
    -Otra razón no especificada que, en opinión del investigador o de Biogen Idec, haga que el paciente no sea apto para la inscripción.
    -Para el subgrupo de pacientes para FD/FC: pacientes incapaces de ingerir la cápsula de BG00012 entera.
    Historia de tratamiento clave:
    - Cualquier tratamiento previo con Fumaderm® o BG00012.
    - Tratamiento previo con cualquiera de los siguientes: Irradiación linfática total, Cladribina, Vacuna de linfocitos T o de receptores de linfocitos T, Cualquier anticuerpo monoclonal terapéutico, a excepción de rituximab o natalizumab
    - Tratamiento previo en los 12 meses anteriores al día 1 con cualquiera de los siguientes medicamentos: Mitoxantrona, Ciclofosfamida, Rituximab.
    - Tratamiento previo en los 6 meses anteriores al Día 1 con cualquiera de los siguientes medicamentos: Fingolimod, Teriflunomida, Natalizumab, Ciclosporina, Azatioprina, Metotrexato, Micofenolato de mofetilo, Laquinimod, Inmunoglobulina intravenosa, Plasmaféresis o citoféresis
    - Tratamiento previo en los 3 meses anteriores al Día 1 con cualquiera de los siguientes medicamentos: Acetato de glatirámero, Interferón ?, Interferón ? (los pacientes que obtengan un resultado positivo para los anticuerpos neutralizadores del interferón ? pueden recibir el tratamiento con interferón ? hasta dos semanas antes del Día
    -Tratamiento previo en los 30 días anteriores al día 1 con cualquiera de los siguientes medicamentos: Corticosteroides (tratamiento con corticosteroides por vía IV u oral, que incluye fármacos que pueden actuar mediante la vía de los corticosteroides [por ejemplo, naltrexona a bajas dosis]); 4-aminopiridina o productos relacionados (excepto los pacientes que tomen una dosis estable de fampridina de liberación controlada durante 3 meses)
    NOTA: Se pueden aplicar otros criterios de inclusión / exclusión definidos en el protocolo
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint of the study is the proportion of participants free of new/newly enlarging T2 hyperintense lesions on brain MRI scans at Week 96.
    El criterio de valoración principal del estudio es conocer la proporción de pacientes sin lesiones hiperintensas en T2 nuevas o aumentadas en RM cerebrales en la Semana 96.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Day 1 (baseline visit), weeks 24, 48, 72, 96
    Día 1 (visita inicial) semanas 24, 48, 72 y 96.
    E.5.2Secondary end point(s)
    The secondary endpoints of this study are as follows:
    ? Number of new/newly enlarging T2 hyperintense lesions on brain MRI scans at Weeks 24 and 96
    ? Proportion of participants free of new/newly enlarging T2 hyperintense lesions on brain MRI scans at Weeks 24 and 48
    ? Proportion of participants free of new MRI activity as measured by brain MRI scans (new MRI activity includes: Gd enhancing MRI lesion on brain MRI scans; new T2 MRI lesions on brain MRI scans and newly enlarging LRI lesions on brain MRI scans) at Weeks 24, 48, and 96
    ? Time to first relapse up to week 96
    ? Proportion of participants who do not experience relapse up to Week 96
    ? Annualized relapse rate at Weeks 48 and 96
    ? Number of participants that experience adverse events (AEs) and serious adverse events (SAEs), including prospective and follow up of flushing, nausea, abdominal pain, and diarrhea up to week 96
    ? Participants receiving BG00012 who consent to participate in the PD/PK subset - PK parameters derived from PK subset data analysis: area under the concentration time curve from time 0 to 10 hours (AUC0 10), maximum observed plasma concentration (Cmax), time to reach maximum observed plasma concentration (Tmax), lag time, elimination half-life (t½), apparent clearance (Cl/F), and apparent volume of distribution (V/F) up to week 4
    ? Participants receiving BG00012 who consent to participate in the PD/PK subset - PD parameters, derived from PD subset data analysis: changes in the nuclear factor (erythroid derived 2) like 2 activation pathway markers quinone 1 (NQO 1) and heme oxygenase 1 (HO 1)up to week 4
    ? Fatigue as measured by the Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale scores (Multidimensional Fatigue Scale scores designed as a generic symptomspecific instrument to measure fatigue in patients with acute and chronic health conditions as well as healthy school and community populations.) up to week 96
    ? Quality of Life as measured by the PedsQL up to week 96
    ? Change from baseline to Week 96 in the Expanded Disability Status Scale (EDSS score; The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam? to (5) = ambulatory without aid or rest for 200 meters? disability severe enough to impair full daily activities? to (10) = death due to MS.) up to week 96
    ? Vital signs, electrocardiograms (ECGs) and changes in clinical laboratory data, including monitoring of liver function, renal function, hematologic and coagulation parameters up to week 96
    ? Other pre-specified outcomes
    Los criterios de valoración secundarios de este estudio son los siguientes:
    ? Número de lesiones hiperintensas en T2 nuevas o aumentadas en RM cerebrales en las Semanas 24 y 96.
    ? La proporción de pacientes sin lesiones hiperintensas en T2 nuevas o aumentadas en RM cerebrales en las Semanas 24 y 48.
    ? Proporción de pacientes sin actividad nueva en la RM (es decir, sin lesiones potenciadas con gadolinio y sin lesiones en T2 nuevas o aumentadas en RM cerebrales) en las Semanas 24, 48 y 96.
    ? Tiempo hasta la primera recaída.
    ? Proporción de pacientes sin recaídas hasta la Semana 96.
    ? Tasa anual de recaídas en las Semanas 48 y 96.
    ? Incidencia de AA y acontecimientos adversos graves (AAG), incluyendo seguimiento posterior del rubor, náuseas, dolor abdominal y diarrea.
    ? Constantes vitales, electrocardiogramas (ECG) y variaciones en los datos de análisis clínicos, incluidos la función hepática y renal y los parámetros hematológicos y de coagulación.
    ? Parámetros FC de BG00012 provenientes del análisis de datos del subgrupo de FC: área bajo la curva de concentración plasmática y tiempo de 0 a 10 horas (ABC0-10), concentración plasmática máxima observada (Cmáx), tiempo hasta alcanzar la concentración plasmática máxima (Tmáx), periodo de latencia, semivida de eliminación (t½), aclaramiento aparente (Cl/F) y volumen de distribución aparente (V/F).
    ? Parámetros FD, provenientes del análisis de datos del subgrupo de FD: variaciones en los marcadores de la vía de activación del factor nuclear (derivado de eritroide 2) relacionado con el factor 2, la nicotinamida adenina dinucleótido fosfato [NAD(P)H] deshidrogenasa, quinona oxidorreductasa 1 (NQO-1) y la hemo oxigenasa 1 (HO-1).
    ? Medición del cansancio mediante las puntuaciones de la Escala multidimensional de cansancio según el PedsQL.
    ? Medición de la calidad de vida según el PedsQL.
    ? Cambio en la puntuación de la EDSS desde el inicio hasta la Semana 96.
    E.5.2.1Timepoint(s) of evaluation of this end point
    The various secondary endpoints will be measured throughout the study as defined by the Schedule of Events. Specifically there are visits at Day 1 (baseline) weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96 and a safety follow-up visit at week 100. There is also a safety telephone call at week2.
    Los diversos criterios de valoración secundarios se medirán a lo largo del estudio como lo define el Programa de Eventos. Especificamente hay visitas en el Día 1 (visita inicial) las semanas 4, 8, 12, 24, 36, 48, 60, 72, 84, 96 y una visita de seguimiento de seguridad en la semana 100. También hay una llamada telefónica seguridad en semana 2 .
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA43
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Belgium
    Canada
    Croatia
    Czech Republic
    Denmark
    France
    Hungary
    Israel
    Italy
    Poland
    Portugal
    Romania
    Serbia
    Spain
    Sweden
    Turkey
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS: The end of study is last subject, last visit for final collection of data for the primary outcome
    LVLS: El fin del estudio es el último sujeto y la última visita para la recogida de datos para el resultado primario
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 142
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 20
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 122
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 114
    F.4.2.2In the whole clinical trial 142
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects who choose not to enroll in the extension study will have a Safety Follow-Up Visit 4 weeks after taking the final dose. Subjects who withdraw prematurely will complete the Early Withdrawal Visit and the Safety Follow-Up Visit 4 weeks after taking their final dose.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-03-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-06-05
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA